Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous FleetsGlobe News Wire · Oct 12, 2026
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement DisorderGlobeNewsWire · Oct 8, 2026
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDAGlobeNewsWire · Oct 7, 2026
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine CombinationsTheNewswire · Sep 23, 2026
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine CombinationsGlobeNewsWire · Sep 23, 2026
Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property PortfolioTheNewswire · Sep 17, 2026Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors.